Agenus (NASDAQ:AGEN) Upgraded at StockNews.com

StockNews.com upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a research report sent to investors on Friday.

Other equities analysts have also issued research reports about the stock. Robert W. Baird dropped their price objective on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, March 12th. HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Tuesday, March 18th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.75.

Agenus Stock Down 3.6 %

Agenus stock opened at $1.61 on Friday. The business’s 50-day moving average price is $3.01 and its two-hundred day moving average price is $3.66. The stock has a market cap of $40.75 million, a PE ratio of -0.14 and a beta of 1.23. Agenus has a 12-month low of $1.60 and a 12-month high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million. As a group, analysts expect that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently bought and sold shares of the business. B. Riley Financial Inc. purchased a new position in shares of Agenus during the fourth quarter valued at approximately $2,074,000. Gilead Sciences Inc. purchased a new stake in shares of Agenus in the fourth quarter worth $635,000. Walleye Capital LLC purchased a new stake in shares of Agenus in the third quarter worth $1,003,000. Jane Street Group LLC grew its stake in Agenus by 97.6% during the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 52,215 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in Agenus by 538.4% during the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 51,566 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.